Cue Biopharma (CUE) Competitors $0.83 +0.01 (+1.80%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.83 +0.00 (+0.48%) As of 08/22/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. TKNO, SCPH, ALLO, SGMT, SOPH, AARD, FENC, TLSA, GALT, and ALECShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Galectin Therapeutics (GALT), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics Alector Cue Biopharma (NASDAQ:CUE) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Is CUE or TKNO more profitable? Alpha Teknova has a net margin of -55.24% compared to Cue Biopharma's net margin of -469.35%. Alpha Teknova's return on equity of -26.51% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-469.35% -230.13% -111.16% Alpha Teknova -55.24%-26.51%-18.40% Does the media prefer CUE or TKNO? In the previous week, Cue Biopharma had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Cue Biopharma and 0 mentions for Alpha Teknova. Cue Biopharma's average media sentiment score of 0.19 beat Alpha Teknova's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the media. Company Overall Sentiment Cue Biopharma Neutral Alpha Teknova Neutral Which has more risk & volatility, CUE or TKNO? Cue Biopharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Do analysts prefer CUE or TKNO? Alpha Teknova has a consensus target price of $10.00, indicating a potential upside of 110.53%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders and institutionals believe in CUE or TKNO? 35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by company insiders. Comparatively, 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, CUE or TKNO? Alpha Teknova has higher revenue and earnings than Cue Biopharma. Alpha Teknova is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M6.83-$40.67M-$0.56-1.48Alpha Teknova$37.74M6.73-$26.75M-$0.42-11.31 SummaryAlpha Teknova beats Cue Biopharma on 11 of the 17 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.35M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-1.4720.8831.1026.05Price / Sales6.83342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book3.448.129.536.61Net Income-$40.67M-$54.72M$3.26B$265.56M7 Day PerformanceN/A2.63%2.10%1.97%1 Month Performance-7.19%2.78%2.81%-0.36%1 Year Performance7.34%11.01%30.56%19.03% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma2.6826 of 5 stars$0.83+1.8%N/A+1.3%$62.35M$9.29M-1.4760News CoverageTKNOAlpha Teknova1.8871 of 5 stars$4.41-6.0%$10.00+126.8%-3.5%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5463 of 5 stars$4.78+3.9%$14.00+192.9%-5.6%$245.17M$49.97M-2.6430Short Interest ↓ALLOAllogene Therapeutics2.8605 of 5 stars$1.09-0.9%$8.44+674.7%-54.1%$244.07M$20K-0.98310SGMTSagimet Biosciences3.2428 of 5 stars$7.55-1.6%$25.67+240.0%+144.3%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9803 of 5 stars$3.49+0.6%$8.00+129.2%+2.0%$234.50M$65.17M-7.93520Positive NewsGap UpAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018News CoverageAnalyst RevisionFENCAdherex Technologies1.8762 of 5 stars$8.20-1.9%$13.33+62.6%+57.5%$232.52M$47.54M-19.5210Analyst ForecastAnalyst RevisionTLSATiziana Life Sciences0.7184 of 5 stars$1.89-4.1%N/A+64.8%$230.19MN/A0.008GALTGalectin Therapeutics2.2531 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099ALECAlector3.9134 of 5 stars$2.13-5.3%$4.17+95.6%-50.3%$227.73M$100.56M-1.84270 Related Companies and Tools Related Companies Alpha Teknova Alternatives scPharmaceuticals Alternatives Allogene Therapeutics Alternatives Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Aardvark Therapeutics Alternatives Adherex Technologies Alternatives Tiziana Life Sciences Alternatives Galectin Therapeutics Alternatives Alector Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access